查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2150667

脂質體阿黴素市場報告：趨勢、預測和競爭分析（至2035年）

Liposomal Doxorubicin Market Report: Trends, Forecast and Competitive Analysis to 2035
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

脂質體阿黴素市場

全球脂質體阿黴素市場前景廣闊，在乳癌、卵巢癌、愛滋病相關卡波西氏肉瘤和多發性骨髓瘤等領域均蘊藏著巨大的市場機會。預計全球脂質體阿黴素市場規模將從2027年的16億美元成長至2035年的27億美元，2027年至2035年的複合年成長率（CAGR）為7.4%。推動該市場成長的關鍵因素包括標靶癌症療法的日益普及、對先進化療需求的成長以及對藥物傳遞效率的日益重視。

  • 根據 Lucintel 的預測，在產品類型中，由於學名藥的價格低於品牌藥，像「Lipodox」這樣的學名藥預計將在預測期內呈現最高的成長率。
  • 從指標來看，由於乳癌病例的增加，預計乳癌領域在整個預測期內將呈現最高的成長率。
  • 從區域上看，由於北美癌症發生率高且腫瘤服務基礎設施完善，預計北美在整個預測期內將呈現最高的成長率。

脂質體阿黴素市場的新趨勢

隨著新的癌症適應症以及更具標靶性和安全性的化療給藥方式的開發，脂質體阿黴素市場預計將在未來幾年內成長。預計在2025年至2027年間，癌症患者確診人數將會增加，同時由於專利到期，市場競爭也會加劇。此外，生產技術的進步也值得期待。 Lucintel預測，屆時心臟安全性將成為癌症治療決策中最重要的考量。

  • 標靶癌症治療：癌症治療的進展可望催生新型脂質體阿黴素製劑，這些製劑可選擇性地向腫瘤釋放藥物。在醫療領域，釋放時間較長、心臟毒性較低的藥物產品可能成為優先考慮的對象。
  • 聯合治療：在此期間，預計脂質體阿黴素將與其他標靶治療、免疫療法和/或其他化療合併使用。目前，大多數使用脂質體阿黴素與其他藥物合併治療多發性骨髓瘤的臨床試驗正在進行中。預計到2026年，其中一些聯合治療將獲得批准並納入醫療保險。 2026年後，預計會有更多使用脂質體阿黴素的聯合治療獲得批准並應用於臨床實踐。
  • 生物相似藥和學名藥帶來的價格壓力：預計未來幾年將有多種脂質體阿黴素生物相似藥上市，這些產品滲透到的市場價格預計將大幅下降。因此，醫療服務提供者需要根據預期療效，做出重要的價值導向決策，選擇使用哪種脂質體阿黴素產品。
  • 生產過程現代化：脂質體製劑生產商正在加強其生產流程，以應對脂質體包封的挑戰，目標是在市售產品中實現 90% 以上的藥物包封率。
  • 新基本客群（地理市場多元化）：由於癌症藥物供不應求持續存在，客戶正在尋找替代供應商。 2024年，美國醫療保健系統藥劑師協會（ASHP）報告稱，美國市場存在323種藥物短缺。 2020年至2030年間，歐洲和亞太地區的產能擴張程度將決定市場進入、定價和庫存水準。

未來幾年，脂質體阿黴素市場預計將呈現橫向成長而非縱向成長。其他抗癌藥物的脂質體製劑預計也將進入市場，其價格預計會低於脂質體阿黴素。為了維持市場地位，脂質體阿黴素生產商需要確保產品無菌供應的持續穩定，並盡可能將產品與其他抗癌藥物合併使用。

脂質體阿黴素市場近期趨勢

2025年至2027年間，受學名藥生產商進入市場、新型抗癌藥物臨床試驗取得積極成果以及對低毒性化療藥物需求不斷成長的推動，脂質體阿黴素市場競爭預計將加劇。預計不久的將來，脂質體阿黴素將獲得新的適應症批准。 Lucintel預測，未來幾年癌症治療需求將會增加，這將促使醫院治療方案發生變化，納入脂質體阿黴素和其他抗體藥物複合體（ADC）的使用。

  • 新學名藥：預計FDA將於2025年批准脂質體阿黴素注射液（20毫克/毫升和50毫克/毫升），這將增加供應商數量並緩解藥品短缺。然而，在未來幾年內，保險報銷方案預計將主導醫院對脂質體阿黴素的支付。
  • 契約製造：此外，一家歐洲契約製造公司宣布將於2025年新建一座無菌藥品生產廠。預計這將增加歐洲市場脂質體製劑的供應量。
  • 聯合治療臨床試驗：聚乙二醇化脂質體阿黴素（PLD）正與免疫療法和其他藥物聯合進行臨床開發。一項涉及120名患者的II期臨床試驗已於2025年啟動。該試驗表明，人們對聯合治療治療卵巢癌、乳癌和血液系統腫瘤的興趣日益濃厚。
  • 專業腫瘤合作：其他公司在其管轄範圍之外授權和/或銷售脂質體阿黴素 (LIPDOX)。 2025 年 LIPDOX 協議涵蓋東南亞地區。專業合作夥伴公司可以在已授權或銷售的地區提供 LIPDOX/PLD，並且註冊和商業化的責任可以轉移給這些合作夥伴公司。
  • 製劑創新：目前，幾種具有改良藥物動力學特性的多柔比星製劑正處於不同的研發階段。如果證實其安全性有所提高，這些改良製劑有望獲得更高的價格，並取代第一代聚乙二醇化製劑。

未來3-5年，LIPDOX/PLD成長的主要驅動力預計將是產品差異化以及無菌產品穩定可靠的供應，而非癌症發生率的變化。由於其生物學和化學性質的複雜性，LIPDOX/PLD的價格可能仍將居高不下。該產品的市場將主要由保險公司決定。供應商可以透過改進產品組合和最佳化監管策略來維持或擴大市場佔有率。未能實現差異化的供應商將因價格下降而失去市場佔有率。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景與分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球脂質體阿黴素市場：依產品分類

  • 吸引力分析：按產品
  • Doxil/凱利克斯
  • Lipodox
  • Myocet
  • 其他

第5章：全球脂質體阿黴素市場：依分銷管道分類

  • 吸引力分析：按分銷管道分類
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章 全球脂質體阿黴素市場：依應用領域分類

  • 吸引力分析：依目的
  • 乳癌
  • 卵巢癌
  • 愛滋病相關卡波西氏肉瘤
  • 多發性骨髓瘤
  • 其他

第7章 區域分析

第8章：北美脂質體阿黴素市場

  • 北美脂質體阿黴素市場：依產品分類
  • 北美脂質體阿黴素市場：按應用領域分類
  • 美國脂質體阿黴素市場
  • 加拿大脂質體阿黴素市場
  • 墨西哥脂質體阿黴素市場

第9章：脂質體阿黴素的歐洲市場

  • 歐洲脂質體阿黴素市場：依產品分類
  • 歐洲脂質體阿黴素市場：按應用領域分類
  • 德國脂質體阿黴素市場
  • 法國脂質體阿黴素市場
  • 義大利脂質體阿黴素市場
  • 西班牙脂質體阿黴素市場
  • 英國脂質體阿黴素市場

第10章：亞太地區脂質體阿黴素市場

  • 亞太地區脂質體阿黴素市場：依產品分類
  • 亞太地區脂質體阿黴素市場：依應用領域分類
  • 中國脂質體阿黴素市場
  • 印度脂質體阿黴素市場
  • 日本脂質體阿黴素市場
  • 韓國脂質體阿黴素市場
  • 印尼脂質體阿黴素市場

第11章：世界其他地區脂質體阿黴素市場

  • 其他地區的脂質體阿黴素市場：依產品分類
  • 其他區域脂質體阿黴素市場：依應用
  • 中東市場對脂質體阿黴素的需求
  • 脂質體阿黴素的南美洲市場
  • 脂質體阿黴素的非洲市場

第12章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第13章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 新趨勢：全球脂質體阿黴素市場
  • 戰略分析

第14章：價值鏈中關鍵企業的公司概況

  • 競爭分析概述
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Cipla
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Lupin
  • Cadila Pharmaceuticals
  • SRS Life Sciences
  • GSK plc
  • Pfizer Inc.

第15章附錄

Liposomal Doxorubicin Market

The future of the global liposomal doxorubicin market looks promising with opportunities in the breast cancer, ovarian cancer, AIDS-related kaposi's sarcoma, and multiple myeloma markets. The global liposomal doxorubicin market is expected to reach an estimated $2.7 billion by 2035 from $1.6 billion in 2027 with a CAGR of 7.4% from 2027 to 2035. The major drivers for this market are the increasing adoption of targeted cancer therapies, the rising demand for advanced chemotherapy treatments, and the growing focus on drug delivery efficiency.

  • Lucintel forecasts that, within the product category, lipodox is expected to witness the highest growth over the forecast period due to less expensive than branded alternatives.
  • Within the application category, breast cancer is expected to witness the highest growth over the forecast period due to increasing breast cancer cases.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to combined high prevalence of cancer and a well-developed oncology service infrastructure.

Emerging Trends in Liposomal Doxorubicin Market

The liposomal doxorubicin market is expected to grow in the next few years as new oncology indications and more targeted, safe, chemotherapy delivery methods are developed. Between 2025 and 2027, more patients are expected to be diagnosed with cancer, and Patents will expire, resulting in increased competition. Additionally, advancements in manufacturing will occur. Lucintel expects that, by this time, Cardiac safety would be the most important consideration when deciding on the treatment of cancer.

  • Targeted Oncology: Advances in oncology are expected to result in new liposomal doxorubicin products that have tumour-selective release. Products with prolonged release times and reduced cardiac toxicity will be prioritized by the medical community.
  • Combination Therapy: During this same time period, it is expected that liposomal doxorubicin will be combined with other targeted therapies, immunotherapies and/or other chemo-therapies. Currently, the majority of clinical trials that combine liposomal doxorubicin with other agents are being conducted in the treatment of multiple myeloma. It is expected that, by 2026, several of these combination therapies would be approved and reimbursed. After 2026, it is expected that additional combinations of liposomal doxorubicin will be approved and integrated into clinical practice.
  • Biosimilar and Generic Pressure: With several biosimilar liposomal doxorubicin products expected to enter the market in the next few years, the price of these products is expected to decrease significantly in the markets that they penetrate. As a result, providers would be required to make important value-based decisions as to which liposomal doxorubicin products to use based upon the outcomes expected.
  • Modernization of Manufacturing: Producers of liposomal formulations are enhancing their manufacturing processes to meet the challenges of liposome encapsulation, and commercial products are aimed at achieving a drug encapsulation efficiency of 90% or more.
  • Newer Customer Base (Geographic Market Diversification): As drug shortages of cancer products persist, customers are seeking alternate suppliers. In 2024, the American Society of Health-System Pharmacists (ASHP) reported 323 active drug shortages in the U.S. Market access, pricing and inventory levels will be determined by the degrees of regional-capacity expansions in Europe and Asia-Pacific between 2020 and 2030.

In the coming years, we expect the market for liposomal doxorubicin to experience more lateral than vertical growth. Liposomal formulations of other anti-cancer drugs are expected to enter the market, and we expect they will be priced lower than liposomal doxorubicin. To sustain their positions in the market, liposomal doxorubicin manufacturers will need to ensure the uninterrupted and sterile supply of their product, and if possible, combine their product with other anti-cancer drugs.

Recent Developments in the Liposomal Doxorubicin Market

Competition for the liposomal doxorubicin market will increase during the period 2025-2027 as a result of the entry of generic players, positive clinical trials for new anti-cancer drugs, and growing demand for lower-toxicity chemotherapy drugs. It is expected that in the foreseeable future, new indications will be granted for liposomal doxorubicin. Lucintel expects that cancer treatment will increase in the coming years, and with that, hospital protocols will change to include the use of liposomal doxorubicin and other antibody-drug conjugates.

  • New Generics: In 2025, the FDA is expected to grant approval for a doxorubicin liposome injection, 20 mg/ml and 50 mg/ml, resulting in more suppliers and hopefully no more drug shortages. It is, however, expected that in the coming years, reimbursement will drive payment for liposomal doxorubicin by hospitals.
  • Contract Manufacturing: Additionally, in 2025, a contract manufacturer in Europe announced it will build a new facility to produce sterile drug products, which will increase the supply of liposomal drugs in the European market.
  • Combination Therapy Trials: Clinical development of pegylated liposomal doxorubicin (PLD) is occurring with immunotherapies and other agents. A phase 2 trial started in 2025, and includes 120 patients. This trial shows an emerging interest in combinations for treatments of cancers of the ovary, breast and blood.
  • Specialty Oncology Partnerships: Other companies are licensing and/or distributing liposomal doxorubicin (LIPDOX) in areas outside of their jurisdiction. The 2025 LIPDOX contract involved Southeast Asia. Specialty partners can make LIPDOX/PLD available in areas where it is license/distributed, and shift the responsibility for registration and commercialization to these partners.
  • Formulation Innovation: Competing formulations of doxorubicin with improved pharmacokinetics are in various stages of development. If improved safety is demonstrated, enhanced formulations may command a price premium and displace first generation pegylated formulations.

It is expected that during the next 3-5 years, the main drivers of growth for LIPDOX/PLD will be differentiation, and reliable and consistent supply of a sterile product, as opposed to changes in cancer prevalence. LIPDOX/PLD will remain expensive due to its biological and chemical complexity. Payer organizations will primarily determine the markets in which the product is available. Improved combinations and/or regulatory strategy will allow suppliers to maintain or increase market share. Undifferentiated suppliers will lose share through price cutting.

Strategic Growth Opportunities in the Liposomal Doxorubicin Market

Commercial potential for liposomal doxorubicin will increase during the 2024-2026 period with the change in the focus of oncology to targeted, out-patient, and less toxic cancer therapy. Lucintel's project interest covers specialty-generic, combination, and access pharmaceutical therapies. Positive trend in cancer incidence, along with clarity in the regulatory environment, has led to increased interest in previously unstudied indications.

  • Combination Oncology Regimens: The use of liposomal doxorubicin in combination with other drugs to form a combination oncology regimen will create a value market during the 2024-2028 period, particularly in cases where the formation of cumulative cardiac toxicity potential limits the use of other anthracycline drugs. During the 2025-2027 period, combination oncology regimens will be the focus of pharmaceutical research. -
  • Hematologic Malignancies: Use of liposomal doxorubicin will increase in hematologic malignancies and multiple myeloma. The National Cancer Institute also listed liposomal doxorubicin for treatment of other hematologic malignancies. The increased use will be for patients who have undergone previous treatment.
  • Access To Emerging Markets: Localized fill-finish, price competition from biosimilars, and government tenders can provide access to more affordable markets including Asia, Latin America and the Middle East. The WHO Model List of Essential Medicines (March 2025) included 22 cancer medicines, promoting the sourcing of affordable cancer medicines. Price-access strategies will be more effective in increasing volume of sales as compared to strategy focused on charging a premium.
  • New Liposomal Technologies: Over the next several years, premium pricing may be justified for oncology products with improved tumour accumulation and/or reduced hand foot syndrome. In April 2025, there were a number of clinical trials for the use of pegylated liposomal doxorubicin at a dose of 40 mg/m2. In the same time frame, sponsors of oncology products may be able to differentiate their products based on liposomal formulations.
  • Outpatient and Home-based Cancer Treatment: There is a trend to administer cancer medicinal products through the outpatient and/or ambulatory route. Such products would require an extended and/or continuous infusion. In addition, the sponsor of the product would need to ensure a stable supply of the product. In May 2025, the Centers for Medicare and Medicaid Services (CMS) of the U.S. continued to reimburse certain outpatient oncology services. There will be a focus on reducing total cost of treatment and increasing efficiency of medical personnel.

Manufacturers are advised to focus on the inter-section of performance, access and evidence to improve their returns. It is particularly important for manufacturers to focus on local and regional regulations to improve access and reliability of supply of their products. The strongest returns will be from products that address toxicity of cancer medicinal products and facilitate outpatient treatments.

Liposomal Doxorubicin Market Drivers and Challenges

Liposomal doxorubicin market trends and factors include local technology and oncology industry development, the economy, and regulations. Increasing demand for cancer treatments and improvement in cancer drug delivery methods created market opportunities, but challenged it with price competition and restrictions. According to Lucintel, market trends will be affected by ongoing economic and technological developments in the health care industry of both developed and developing countries.

The factors responsible for driving this market include:

  • Demand from Patients: Increased cancer cases have created an increasing demand for liposomal doxorubicin for the treatment of cancers such as breast, ovary and hematological malignancies. Compared to other doxorubicin based treatments, liposomal doxorubicin has fewer patient toxicities and is well accepted by oncologists. The American Cancer Society estimated 2,092,870 new cancer cases in the US for 2025. The 3 to 5 year target aging population along with greater accessibility of cancer treatment is expected to create continuous demand for liposomal doxorubicin.
  • Delivery Technology: Research advances in oncology promote the development of next-generation delivery systems. The past year (2025) has seen continued investment in nanotechnology-based delivery systems for oncology. Advances in the manufacture of delivery systems are expected to result in improved formulations with enhanced performance. Development in this area may result in delivery systems that target tumour cells and/or tissue. The formulation of combination therapies and improved consistency of formulations may allow tumour treatment to extend beyond the oncology setting to include the treatment of other cancers. The next 5 years may see an increasing number of oncology products entering the market.
  • Regulatory Support: The introduction and revision of guidelines by regulatory agencies facilitates the development and introduction of new oncology products. Guidelines that promote the development of targeted therapies, e.g. therapy for rare cancers, further encourage and facilitate the development of new cancer products. In 2025, guidelines emphasized the need for the development of safe and effective cancer products and the importance of the comparability of drug products.
  • Healthcare Investment: Increased spending in cancer care has led to development of cancer-specific hospitals and infusion centres and improved diagnostic facilities. This has improved the access to cancer medicines including novel, advanced and injectable therapies. This trend is notable in Asia-Pacific, Latin America and the Middle East. Stronger country-level cancer control strategies focused on improving access and timeliness of cancer care have been adopted. In the next 3 to 5 years, there will be improved infrastructure to offer cancer care, especially in low- and middle-income countries (LMICs). Uniformity of cancer care will, however, remain unacceptable due to lack of cancer-specific workforce and health financing.
  • Manufacturing Improvement: Reliable and improved supply of medicines has been limited due to numerous challenges faced by pharmaceutical companies. Aseptic processing of medicinal products, including liposomal products, requires very stringent processes to ensure the integrity of the loaded drug and its release. Injectable products, by nature, require very stringent processes to ensure the end-product is free from any contaminants. Continuous improvements in processes and integration of automation in manufacturing will enhance reliability of injectable medicinal products and reduce their costs. In the next 3 to 5 years, this will result in improved supply and reduced regulatory and health care system challenges.

The challenges facing this market include:

  • Higher Development Costs: The development of Liposomal Doxorubicin requires expensive equipment and precise production and control processes. Evidence shows that manufacturing Liposomal Doxorubicin poses a challenge for emerging market and generics companies. In August 2025, pharma companies continued to invest in the development of complex injectable products because traditional bioequivalence tests do not evaluate equivalence. In the next 3 to 5 years, only a few companies will be able to manufacture Liposomal Doxorubicin because of the high costs. The rest of the companies will use strategies like manufacturing under a license or manufacturing it for other companies.
  • Pricing and Reimbursement: In October 2025, certain healthcare systems had ongoing initiatives to negotiate the price of cancer drugs and establish value-based contracts. Other systems contracted suppliers of cancer drugs to achieve better outcomes for patients. The suppliers that focused on value had a competitive edge. In the next 3 to 5 years, it is expected that value-based contracts will be negotiated for most of the cancer drugs and manufacturers will focus on offering added value by means of improving the reliability of the supply, offering patient support services and creating combination drugs.
  • Supply Chain and Quality Risk: The production of liposomal products requires specialized ingredients and facilities, as well as validated packaging and storage. Disruptions at any point in the process may result in a lack of treatment options for patients. In May 2025, disruptions in global pharmaceutical supply chains negatively impacted the supply of complex injectables. It is anticipated that in the next three to five years, in order to minimize supply chain risks, manufacturers would employ a range of strategies, including the use of multiple suppliers, local manufacturing, and enhanced inventory and quality controls. While the use of these strategies may increase the cost of products, it is anticipated that liposomal doxorubicin and similar products would remain in high demand and gain greater market penetration in both established and new/emerging markets.

Although manufacturing and market constraints are expected to impact the rate of market penetration, the net effect of these constraints would likely be positive and strengthen market positioning. The relative positioning of market participants would likely depend on the outcome of concurrent efforts to develop and commercialize comparable products. It is to be expected that market participants would focus efforts and investments on the improvement of value (quality) and growth (scale) to gain market position and sustainability.

List of Liposomal Doxorubicin Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies liposomal doxorubicin market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liposomal doxorubicin market companies profiled in this report include-

  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Cipla
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Lupin
  • Cadila Pharmaceuticals
  • SRS Life Sciences
  • GSK plc
  • Pfizer Inc.

Liposomal Doxorubicin Market by Segment

The study includes a forecast for the global liposomal doxorubicin market by product, distribution channel, application, and region.

Liposomal Doxorubicin Market by Product [Value ($B) from 2019 to 2035]:

  • Doxil/Caelyx
  • Lipodox
  • Myocet
  • Others

Liposomal Doxorubicin Market by Distribution Channel [Value ($B) from 2019 to 2035]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Liposomal Doxorubicin Market by Application [Value ($B) from 2019 to 2035]:

  • Breast Cancer
  • Ovarian Cancer
  • AIDS-related Kaposi's Sarcoma
  • Multiple Myeloma
  • Others

Liposomal Doxorubicin Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Liposomal Doxorubicin Market

Between 2025 and 2027, increased generic competition and more stringent supply chain management by manufacturers will be the main trends in the liposomal doxorubicin market. Agencies such as the Food and Drug Administration (FDA) will look to ensure manufacture and distribution of safe and effective liposomal doxorubicin. With this situation, Lucintel expects the trends in the liposomal doxorubicin market will remain the same.

  • United States: United States, the liposomal doxorubicin market will favour manufacturers who can secure distribution to hospitals from reliable and consistent sources. Manufacturing to higher standards set by the FDA along with increased competition will help alleviate the drug shortages reported by the FDA. In March 2025, the FDA reported 323 drug shortages.
  • China: China will also follow similar trends as local manufacturers strengthen their capabilities to produce more advanced injectable pharmaceuticals. Along with this trend, there will be increased demand and supply of liposomal doxorubicin in China.
  • Germany: Leading German pharmaceutical manufacturers have invested in high-containment and aseptic processes to manufacture oncology medicines. In February 2025, the EMA announced 104 medicinal products authorized for marketing, including advanced therapies. German pharmaceutical companies are expected to continue investing to capitalize on the opportunities created by the centralized nature of EMA processes and requirements.
  • India: India's central and state governments have also launched production-linked incentive and similar schemes focused on the pharmaceutical sector. Further, the government announced an increase in the budget for its pharma PLI scheme. This is expected to promote the local production of complex APIs and pharmaceutical intermediates, and finished forms of oncology medicines. Moreover, in line with the 'Make in India' initiative, the government introduced a series of measures to improve the production and supply of pharmaceutical products.
  • Japan: Japan's regulatory body and the pharmaceutical industry have taken a series of measures to ensure an adequate supply of safe and effective injectable medicines. As Japan's population ages and is at a greater risk of developing cancer, there is increased demand for cancer medicines. Alternative liposomal doxorubicin is anticipated to follow a similar trend.

Features of the Global Liposomal Doxorubicin Market

  • Market Size Estimates: liposomal doxorubicin market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: liposomal doxorubicin market size by product, distribution channel, application, and region in terms of value ($B).
  • Regional Analysis: liposomal doxorubicin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different products, distribution channels, applications, and regions for the liposomal doxorubicin market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the liposomal doxorubicin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the liposomal doxorubicin market by product (doxil/caelyx, lipodox, myocet, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (breast cancer, ovarian cancer, aids-related kaposi's sarcoma, multiple myeloma, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Liposomal Doxorubicin Market by Product

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Product
  • 4.3 Doxil/Caelyx : Trends and Forecast 2019 to 2035
  • 4.4 Lipodox : Trends and Forecast 2019 to 2035
  • 4.5 Myocet : Trends and Forecast 2019 to 2035
  • 4.6 Others : Trends and Forecast 2019 to 2035

5. Global Liposomal Doxorubicin Market by Distribution Channel

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Distribution Channel
  • 5.3 Hospital Pharmacies : Trends and Forecast 2019 to 2035
  • 5.4 Retail Pharmacies : Trends and Forecast 2019 to 2035
  • 5.5 Online Pharmacies : Trends and Forecast 2019 to 2035

6. Global Liposomal Doxorubicin Market by Application

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by Application
  • 6.3 Breast Cancer : Trends and Forecast 2019 to 2035
  • 6.4 Ovarian Cancer : Trends and Forecast 2019 to 2035
  • 6.5 AIDS-related Kaposi's Sarcoma : Trends and Forecast 2019 to 2035
  • 6.6 Multiple Myeloma : Trends and Forecast 2019 to 2035
  • 6.7 Others : Trends and Forecast 2019 to 2035

7. Regional Analysis

  • 7.1 Overview
  • 7.2 Global Liposomal Doxorubicin Market by Region

8. North American Liposomal Doxorubicin Market

  • 8.1 Overview
  • 8.2 North American Liposomal Doxorubicin Market by Product
  • 8.3 North American Liposomal Doxorubicin Market by Application
  • 8.4 The United States Liposomal Doxorubicin Market
  • 8.5 Canadian Liposomal Doxorubicin Market
  • 8.6 Mexican Liposomal Doxorubicin Market

9. European Liposomal Doxorubicin Market

  • 9.1 Overview
  • 9.2 European Liposomal Doxorubicin Market by Product
  • 9.3 European Liposomal Doxorubicin Market by Application
  • 9.4 German Liposomal Doxorubicin Market
  • 9.5 French Liposomal Doxorubicin Market
  • 9.6 Italian Liposomal Doxorubicin Market
  • 9.7 Spanish Liposomal Doxorubicin Market
  • 9.8 The United Kingdom Liposomal Doxorubicin Market

10. APAC Liposomal Doxorubicin Market

  • 10.1 Overview
  • 10.2 APAC Liposomal Doxorubicin Market by Product
  • 10.3 APAC Liposomal Doxorubicin Market by Application
  • 10.4 Chinese Liposomal Doxorubicin Market
  • 10.5 Indian Liposomal Doxorubicin Market
  • 10.6 Japanese Liposomal Doxorubicin Market
  • 10.7 South Korean Liposomal Doxorubicin Market
  • 10.8 Indonesian Liposomal Doxorubicin Market

11. ROW Liposomal Doxorubicin Market

  • 11.1 Overview
  • 11.2 ROW Liposomal Doxorubicin Market by Product
  • 11.3 ROW Liposomal Doxorubicin Market by Application
  • 11.4 Middle Eastern Liposomal Doxorubicin Market
  • 11.5 South American Liposomal Doxorubicin Market
  • 11.6 African Liposomal Doxorubicin Market

12. Competitor Analysis

  • 12.1 Product Portfolio Analysis
  • 12.2 Operational Integration
  • 12.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

  • 13.1 Value Chain Analysis
  • 13.2 Growth Opportunity Analysis
    • 13.2.1 Growth Opportunity by Product
    • 13.2.2 Growth Opportunity by Distribution Channel
    • 13.2.3 Growth Opportunity by Application
  • 13.3 Emerging Trends in the Global Liposomal Doxorubicin Market
  • 13.4 Strategic Analysis
    • 13.4.1 New Product Development
    • 13.4.2 Certification and Licensing
    • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

  • 14.1 Competitive Analysis Overview
  • 14.2 Sun Pharmaceutical Industries Ltd.
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.3 Johnson & Johnson Services, Inc.
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.4 Merck & Co., Inc.
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.5 Cipla
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.6 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.7 Lupin
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.8 Cadila Pharmaceuticals
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.9 SRS Life Sciences
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.10 GSK plc
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.11 Pfizer Inc.
    • Company Overview
    • Liposomal Doxorubicin Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

15. Appendix

  • 15.1 List of Figures
  • 15.2 List of Tables
  • 15.3 Research Methodology
  • 15.4 Disclaimer
  • 15.5 Copyright
  • 15.6 Abbreviations and Technical Units
  • 15.7 About Us
  • 15.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Liposomal Doxorubicin Market
  • Figure 2.1: Usage of Liposomal Doxorubicin Market
  • Figure 2.2: Classification of the Global Liposomal Doxorubicin Market
  • Figure 2.3: Supply Chain of the Global Liposomal Doxorubicin Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the Liposomal Doxorubicin Market
  • Figure 4.1: Global Liposomal Doxorubicin Market by Product in 2019, 2026, and 2035
  • Figure 4.2: Trends of the Global Liposomal Doxorubicin Market ($B) by Product
  • Figure 4.3: Forecast for the Global Liposomal Doxorubicin Market ($B) by Product
  • Figure 4.4: Trends and Forecast for Doxil/Caelyx in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Lipodox in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 4.6: Trends and Forecast for Myocet in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 4.7: Trends and Forecast for Others in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 5.1: Global Liposomal Doxorubicin Market by Distribution Channel in 2019, 2026, and 2035
  • Figure 5.2: Trends of the Global Liposomal Doxorubicin Market ($B) by Distribution Channel
  • Figure 5.3: Forecast for the Global Liposomal Doxorubicin Market ($B) by Distribution Channel
  • Figure 5.4: Trends and Forecast for Hospital Pharmacies in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Retail Pharmacies in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Online Pharmacies in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 6.1: Global Liposomal Doxorubicin Market by Application in 2019, 2026, and 2035
  • Figure 6.2: Trends of the Global Liposomal Doxorubicin Market ($B) by Application
  • Figure 6.3: Forecast for the Global Liposomal Doxorubicin Market ($B) by Application
  • Figure 6.4: Trends and Forecast for Breast Cancer in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 6.5: Trends and Forecast for Ovarian Cancer in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 6.6: Trends and Forecast for AIDS-related Kaposi's Sarcoma in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 6.7: Trends and Forecast for Multiple Myeloma in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 6.8: Trends and Forecast for Others in the Global Liposomal Doxorubicin Market (2019-2035)
  • Figure 7.1: Trends of the Global Liposomal Doxorubicin Market ($B) by Region (2019-2026)
  • Figure 7.2: Forecast for the Global Liposomal Doxorubicin Market ($B) by Region (2027-2035)
  • Figure 8.1: Trends and Forecast for the North American Liposomal Doxorubicin Market (2019-2035)
  • Figure 8.2: North American Liposomal Doxorubicin Market by Product in 2019, 2026, and 2035
  • Figure 8.3: Trends of the North American Liposomal Doxorubicin Market ($B) by Product (2019-2026)
  • Figure 8.4: Forecast for the North American Liposomal Doxorubicin Market ($B) by Product (2027-2035)
  • Figure 8.5: North American Liposomal Doxorubicin Market by Distribution Channel in 2019, 2026, and 2035
  • Figure 8.6: Trends of the North American Liposomal Doxorubicin Market ($B) by Distribution Channel (2019-2026)
  • Figure 8.7: Forecast for the North American Liposomal Doxorubicin Market ($B) by Distribution Channel (2027-2035)
  • Figure 8.8: North American Liposomal Doxorubicin Market by Application in 2019, 2026, and 2035
  • Figure 8.9: Trends of the North American Liposomal Doxorubicin Market ($B) by Application (2019-2026)
  • Figure 8.10: Forecast for the North American Liposomal Doxorubicin Market ($B) by Application (2027-2035)
  • Figure 8.11: Trends and Forecast for the United States Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 8.12: Trends and Forecast for the Mexican Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 8.13: Trends and Forecast for the Canadian Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 9.1: Trends and Forecast for the European Liposomal Doxorubicin Market (2019-2035)
  • Figure 9.2: European Liposomal Doxorubicin Market by Product in 2019, 2026, and 2035
  • Figure 9.3: Trends of the European Liposomal Doxorubicin Market ($B) by Product (2019-2026)
  • Figure 9.4: Forecast for the European Liposomal Doxorubicin Market ($B) by Product (2027-2035)
  • Figure 9.5: European Liposomal Doxorubicin Market by Distribution Channel in 2019, 2026, and 2035
  • Figure 9.6: Trends of the European Liposomal Doxorubicin Market ($B) by Distribution Channel (2019-2026)
  • Figure 9.7: Forecast for the European Liposomal Doxorubicin Market ($B) by Distribution Channel (2027-2035)
  • Figure 9.8: European Liposomal Doxorubicin Market by Application in 2019, 2026, and 2035
  • Figure 9.9: Trends of the European Liposomal Doxorubicin Market ($B) by Application (2019-2026)
  • Figure 9.10: Forecast for the European Liposomal Doxorubicin Market ($B) by Application (2027-2035)
  • Figure 9.11: Trends and Forecast for the German Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 9.12: Trends and Forecast for the French Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 9.13: Trends and Forecast for the Spanish Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 9.14: Trends and Forecast for the Italian Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 9.15: Trends and Forecast for the United Kingdom Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the APAC Liposomal Doxorubicin Market (2019-2035)
  • Figure 10.2: APAC Liposomal Doxorubicin Market by Product in 2019, 2026, and 2035
  • Figure 10.3: Trends of the APAC Liposomal Doxorubicin Market ($B) by Product (2019-2026)
  • Figure 10.4: Forecast for the APAC Liposomal Doxorubicin Market ($B) by Product (2027-2035)
  • Figure 10.5: APAC Liposomal Doxorubicin Market by Distribution Channel in 2019, 2026, and 2035
  • Figure 10.6: Trends of the APAC Liposomal Doxorubicin Market ($B) by Distribution Channel (2019-2026)
  • Figure 10.7: Forecast for the APAC Liposomal Doxorubicin Market ($B) by Distribution Channel (2027-2035)
  • Figure 10.8: APAC Liposomal Doxorubicin Market by Application in 2019, 2026, and 2035
  • Figure 10.9: Trends of the APAC Liposomal Doxorubicin Market ($B) by Application (2019-2026)
  • Figure 10.10: Forecast for the APAC Liposomal Doxorubicin Market ($B) by Application (2027-2035)
  • Figure 10.11: Trends and Forecast for the Japanese Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 10.12: Trends and Forecast for the Indian Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 10.13: Trends and Forecast for the Chinese Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 10.14: Trends and Forecast for the South Korean Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 10.15: Trends and Forecast for the Indonesian Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 11.1: Trends and Forecast for the ROW Liposomal Doxorubicin Market (2019-2035)
  • Figure 11.2: ROW Liposomal Doxorubicin Market by Product in 2019, 2026, and 2035
  • Figure 11.3: Trends of the ROW Liposomal Doxorubicin Market ($B) by Product (2019-2026)
  • Figure 11.4: Forecast for the ROW Liposomal Doxorubicin Market ($B) by Product (2027-2035)
  • Figure 11.5: ROW Liposomal Doxorubicin Market by Distribution Channel in 2019, 2026, and 2035
  • Figure 11.6: Trends of the ROW Liposomal Doxorubicin Market ($B) by Distribution Channel (2019-2026)
  • Figure 11.7: Forecast for the ROW Liposomal Doxorubicin Market ($B) by Distribution Channel (2027-2035)
  • Figure 11.8: ROW Liposomal Doxorubicin Market by Application in 2019, 2026, and 2035
  • Figure 11.9: Trends of the ROW Liposomal Doxorubicin Market ($B) by Application (2019-2026)
  • Figure 11.10: Forecast for the ROW Liposomal Doxorubicin Market ($B) by Application (2027-2035)
  • Figure 11.11: Trends and Forecast for the Middle Eastern Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 11.12: Trends and Forecast for the South American Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 11.13: Trends and Forecast for the African Liposomal Doxorubicin Market ($B) (2019-2035)
  • Figure 12.1: Porter's Five Forces Analysis of the Global Liposomal Doxorubicin Market
  • Figure 12.2: Market Share (%) of Top Players in the Global Liposomal Doxorubicin Market (2026)
  • Figure 13.1: Growth Opportunities for the Global Liposomal Doxorubicin Market by Product
  • Figure 13.2: Growth Opportunities for the Global Liposomal Doxorubicin Market by Distribution Channel
  • Figure 13.3: Growth Opportunities for the Global Liposomal Doxorubicin Market by Application
  • Figure 13.4: Growth Opportunities for the Global Liposomal Doxorubicin Market by Region
  • Figure 13.5: Emerging Trends in the Global Liposomal Doxorubicin Market

List of Tables

  • Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Liposomal Doxorubicin Market by Product, Distribution Channel, and Application
  • Table 1.2: Attractiveness Analysis for the Liposomal Doxorubicin Market by Region
  • Table 1.3: Global Liposomal Doxorubicin Market Parameters and Attributes
  • Table 3.1: Trends of the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 3.2: Forecast for the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 4.1: Attractiveness Analysis for the Global Liposomal Doxorubicin Market by Product
  • Table 4.2: Market Size and CAGR of Various Product in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 4.3: Market Size and CAGR of Various Product in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 4.4: Trends of Doxil/Caelyx in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 4.5: Forecast for Doxil/Caelyx in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 4.6: Trends of Lipodox in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 4.7: Forecast for Lipodox in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 4.8: Trends of Myocet in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 4.9: Forecast for Myocet in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 4.10: Trends of Others in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 4.11: Forecast for Others in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 5.1: Attractiveness Analysis for the Global Liposomal Doxorubicin Market by Distribution Channel
  • Table 5.2: Market Size and CAGR of Various Distribution Channel in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 5.3: Market Size and CAGR of Various Distribution Channel in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 5.4: Trends of Hospital Pharmacies in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 5.5: Forecast for Hospital Pharmacies in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 5.6: Trends of Retail Pharmacies in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 5.7: Forecast for Retail Pharmacies in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 5.8: Trends of Online Pharmacies in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 5.9: Forecast for Online Pharmacies in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 6.1: Attractiveness Analysis for the Global Liposomal Doxorubicin Market by Application
  • Table 6.2: Market Size and CAGR of Various Application in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 6.3: Market Size and CAGR of Various Application in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 6.4: Trends of Breast Cancer in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 6.5: Forecast for Breast Cancer in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 6.6: Trends of Ovarian Cancer in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 6.7: Forecast for Ovarian Cancer in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 6.8: Trends of AIDS-related Kaposi's Sarcoma in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 6.9: Forecast for AIDS-related Kaposi's Sarcoma in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 6.10: Trends of Multiple Myeloma in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 6.11: Forecast for Multiple Myeloma in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 6.12: Trends of Others in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 6.13: Forecast for Others in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 7.1: Market Size and CAGR of Various Regions in the Global Liposomal Doxorubicin Market (2019-2026)
  • Table 7.2: Market Size and CAGR of Various Regions in the Global Liposomal Doxorubicin Market (2027-2035)
  • Table 8.1: Trends of the North American Liposomal Doxorubicin Market (2019-2026)
  • Table 8.2: Forecast for the North American Liposomal Doxorubicin Market (2027-2035)
  • Table 8.3: Market Size and CAGR of Various Product in the North American Liposomal Doxorubicin Market (2019-2026)
  • Table 8.4: Market Size and CAGR of Various Product in the North American Liposomal Doxorubicin Market (2027-2035)
  • Table 8.5: Market Size and CAGR of Various Distribution Channel in the North American Liposomal Doxorubicin Market (2019-2026)
  • Table 8.6: Market Size and CAGR of Various Distribution Channel in the North American Liposomal Doxorubicin Market (2027-2035)
  • Table 8.7: Market Size and CAGR of Various Application in the North American Liposomal Doxorubicin Market (2019-2026)
  • Table 8.8: Market Size and CAGR of Various Application in the North American Liposomal Doxorubicin Market (2027-2035)
  • Table 8.9: Trends and Forecast for the United States Liposomal Doxorubicin Market (2019-2035)
  • Table 8.10: Trends and Forecast for the Mexican Liposomal Doxorubicin Market (2019-2035)
  • Table 8.11: Trends and Forecast for the Canadian Liposomal Doxorubicin Market (2019-2035)
  • Table 9.1: Trends of the European Liposomal Doxorubicin Market (2019-2026)
  • Table 9.2: Forecast for the European Liposomal Doxorubicin Market (2027-2035)
  • Table 9.3: Market Size and CAGR of Various Product in the European Liposomal Doxorubicin Market (2019-2026)
  • Table 9.4: Market Size and CAGR of Various Product in the European Liposomal Doxorubicin Market (2027-2035)
  • Table 9.5: Market Size and CAGR of Various Distribution Channel in the European Liposomal Doxorubicin Market (2019-2026)
  • Table 9.6: Market Size and CAGR of Various Distribution Channel in the European Liposomal Doxorubicin Market (2027-2035)
  • Table 9.7: Market Size and CAGR of Various Application in the European Liposomal Doxorubicin Market (2019-2026)
  • Table 9.8: Market Size and CAGR of Various Application in the European Liposomal Doxorubicin Market (2027-2035)
  • Table 9.9: Trends and Forecast for the German Liposomal Doxorubicin Market (2019-2035)
  • Table 9.10: Trends and Forecast for the French Liposomal Doxorubicin Market (2019-2035)
  • Table 9.11: Trends and Forecast for the Spanish Liposomal Doxorubicin Market (2019-2035)
  • Table 9.12: Trends and Forecast for the Italian Liposomal Doxorubicin Market (2019-2035)
  • Table 9.13: Trends and Forecast for the United Kingdom Liposomal Doxorubicin Market (2019-2035)
  • Table 10.1: Trends of the APAC Liposomal Doxorubicin Market (2019-2026)
  • Table 10.2: Forecast for the APAC Liposomal Doxorubicin Market (2027-2035)
  • Table 10.3: Market Size and CAGR of Various Product in the APAC Liposomal Doxorubicin Market (2019-2026)
  • Table 10.4: Market Size and CAGR of Various Product in the APAC Liposomal Doxorubicin Market (2027-2035)
  • Table 10.5: Market Size and CAGR of Various Distribution Channel in the APAC Liposomal Doxorubicin Market (2019-2026)
  • Table 10.6: Market Size and CAGR of Various Distribution Channel in the APAC Liposomal Doxorubicin Market (2027-2035)
  • Table 10.7: Market Size and CAGR of Various Application in the APAC Liposomal Doxorubicin Market (2019-2026)
  • Table 10.8: Market Size and CAGR of Various Application in the APAC Liposomal Doxorubicin Market (2027-2035)
  • Table 10.9: Trends and Forecast for the Japanese Liposomal Doxorubicin Market (2019-2035)
  • Table 10.10: Trends and Forecast for the Indian Liposomal Doxorubicin Market (2019-2035)
  • Table 10.11: Trends and Forecast for the Chinese Liposomal Doxorubicin Market (2019-2035)
  • Table 10.12: Trends and Forecast for the South Korean Liposomal Doxorubicin Market (2019-2035)
  • Table 10.13: Trends and Forecast for the Indonesian Liposomal Doxorubicin Market (2019-2035)
  • Table 11.1: Trends of the ROW Liposomal Doxorubicin Market (2019-2026)
  • Table 11.2: Forecast for the ROW Liposomal Doxorubicin Market (2027-2035)
  • Table 11.3: Market Size and CAGR of Various Product in the ROW Liposomal Doxorubicin Market (2019-2026)
  • Table 11.4: Market Size and CAGR of Various Product in the ROW Liposomal Doxorubicin Market (2027-2035)
  • Table 11.5: Market Size and CAGR of Various Distribution Channel in the ROW Liposomal Doxorubicin Market (2019-2026)
  • Table 11.6: Market Size and CAGR of Various Distribution Channel in the ROW Liposomal Doxorubicin Market (2027-2035)
  • Table 11.7: Market Size and CAGR of Various Application in the ROW Liposomal Doxorubicin Market (2019-2026)
  • Table 11.8: Market Size and CAGR of Various Application in the ROW Liposomal Doxorubicin Market (2027-2035)
  • Table 11.9: Trends and Forecast for the Middle Eastern Liposomal Doxorubicin Market (2019-2035)
  • Table 11.10: Trends and Forecast for the South American Liposomal Doxorubicin Market (2019-2035)
  • Table 11.11: Trends and Forecast for the African Liposomal Doxorubicin Market (2019-2035)
  • Table 12.1: Product Mapping of Liposomal Doxorubicin Suppliers Based on Segments
  • Table 12.2: Operational Integration of Liposomal Doxorubicin Manufacturers
  • Table 12.3: Rankings of Suppliers Based on Liposomal Doxorubicin Revenue
  • Table 13.1: New Product Launches by Major Liposomal Doxorubicin Producers (2019-2026)
  • Table 13.2: Certification Acquired by Major Competitor in the Global Liposomal Doxorubicin Market